6533b857fe1ef96bd12b4f95
RESEARCH PRODUCT
LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY
M. NeufeldG. PleweE. Del PozoJ. BeyerU. Krausesubject
Adultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPeptide hormoneOctreotideEatingSubcutaneous injectionInternal medicineAcromegalymedicineHumansInsulinAgedChemotherapyMealChemistryGeneral MedicineGlucose Tolerance TestMiddle AgedGlucagonmedicine.diseaseGrowth hormone secretionEndocrinologySomatostatinBasal (medicine)Growth HormoneAcromegalySomatostatindescription
In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1984-10-01 | The Lancet |